Abstract
Compliance Aids have gained widespread use to assist patients in managing their medicines, with a view to addressing the issue of adherence. However, although patient outcomes may have been improved through better use of compliance aids, it has been highlighted that there are limited data on the stability of medicines, when removed from the original container and repackaged in a compliance aid. Exposure of medicines to heat, light, moisture and air (oxygen) may impact on both their chemical and physical stability, resulting in the potential for quality of the medicine and thus the safety for the patient being compromised. It is also uncertain whether the compliance aid can provide the same protection from these environmental conditions as the manufacturer’s packaging, even though the time frame for repackaging is only 28 days. This paper presents a comprehensive review and detailed discussion of the available literature on the stability implications of repackaging medicines into compliance aids. The importance of repackaging is thus highlighted by its ability to impact on therapeutic outcomes for patients.
Keywords: Dose Administration Aids, quality, repackaging, safety, stability, storage.
Current Drug Safety
Title:Evidence of Stability of Medicines Repackaged in Compliance Aids: A Review
Volume: 11 Issue: 1
Author(s): Alison Haywood and Beverley D. Glass
Affiliation:
Keywords: Dose Administration Aids, quality, repackaging, safety, stability, storage.
Abstract: Compliance Aids have gained widespread use to assist patients in managing their medicines, with a view to addressing the issue of adherence. However, although patient outcomes may have been improved through better use of compliance aids, it has been highlighted that there are limited data on the stability of medicines, when removed from the original container and repackaged in a compliance aid. Exposure of medicines to heat, light, moisture and air (oxygen) may impact on both their chemical and physical stability, resulting in the potential for quality of the medicine and thus the safety for the patient being compromised. It is also uncertain whether the compliance aid can provide the same protection from these environmental conditions as the manufacturer’s packaging, even though the time frame for repackaging is only 28 days. This paper presents a comprehensive review and detailed discussion of the available literature on the stability implications of repackaging medicines into compliance aids. The importance of repackaging is thus highlighted by its ability to impact on therapeutic outcomes for patients.
Export Options
About this article
Cite this article as:
Haywood Alison and Glass D. Beverley, Evidence of Stability of Medicines Repackaged in Compliance Aids: A Review, Current Drug Safety 2016; 11 (1) . https://dx.doi.org/10.2174/1574886310666150928104931
DOI https://dx.doi.org/10.2174/1574886310666150928104931 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Protein Oxidative Modification in the Aging Organism and the Role of the Ubiquitin Proteasomal System
Current Pharmaceutical Design Nanotechnology Advancements in the Diagnosis and Prevention of COVID-19: Past and Future
Coronaviruses Adipose-Derived Stromal/Stem Cells (ASC) in Regenerative Medicine: Pharmaceutical Applications
Current Pharmaceutical Design The Role of Coronary Physiology in Contemporary Percutaneous Coronary Interventions
Current Cardiology Reviews Metabolic-Inflammatory Changes, and Accelerated Atherosclerosis in HIV Patients: Rationale for Preventative Measures
Current Medicinal Chemistry Effects of Estrogens on Atherogenesis
Current Vascular Pharmacology Nimodipine Reappraised: An Old Drug With a Future
Current Neuropharmacology Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis
Current Drug Targets Non-ACE Pathway-induced Angiotensin II Production
Current Pharmaceutical Design Platelets and Atherothrombosis: Causes, Targets and Treatments for Thrombosis
Current Medicinal Chemistry The Role of P2Y<sub>12</sub> Receptor and Activated Platelets During Inflammation
Current Drug Targets Blood Coagulation and the Risk of Atherothrombosis
Current Genomics The Frequency of Thrombotic Events Among Adults Given Antifibrinolytic Drugs for Spontaneous Bleeding: Systematic Review and Meta-Analysis of Observational Studies and Randomized Trials
Current Drug Safety Is There a True Beneficial Effect of Statin Therapy in the Acute Phase of Unstable Angina or Myocardial Infarction?
Current Vascular Pharmacology Drainage of Cerebral Abscesses Prior to Valve Replacement in Stable Patients with Acute Left-Sided Infective Endocarditis
CNS & Neurological Disorders - Drug Targets Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design Role of Bone-Type Tissue-Nonspecific Alkaline Phosphatase and PHOSPO1 in Vascular Calcification
Current Pharmaceutical Design Imaging and Laboratory Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design COMPLICATIONS OF RECANALIZATION OF CHRONIC TOTAL OCCLUSION
Current Cardiology Reviews